Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23-29 August 2014
|
| In: |
The lancet
Year: 2014, Volume: 384, Issue: 9944, Pages: 665-673 |
| ISSN: | 1474-547X |
| DOI: | 10.1016/S0140-6736(14)60845-X |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1016/S0140-6736(14)60845-X
|
| Author Notes: | Edward B. Garon, Tudor-Eliade Ciuleanu, Oscar Arrieta, Kumar Prabhash, Konstantinos N. Syrigos, Tuncay Goksel, Keunchil Park, Vera Gorbunova, Ruben Dario Kowalyszyn, Joanna Pikiel, Grzegorz Czyzewicz, Sergey V Orlov, Conrad R. Lewanski, Michael Thomas, Paolo Bidoli, Shaker Dakhil, Steven Gans, Joo-Hang Kim, Alexandru Grigorescu, Nina Karaseva, Martin Reck, Federico Cappuzzo, Ekaterine Alexandris, Andreas Sashegyi, Sergey Yurasov, Maurice Pérol |
| Item Description: | Gesehen am 07.03.2016 |
|---|---|
| Physical Description: | Online Resource |
| ISSN: | 1474-547X |
| DOI: | 10.1016/S0140-6736(14)60845-X |